Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Turning Point Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04161391CT.gov Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · RET Fusion Positive Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Enbezotinib (this asset) | Turning Point Therapeutics, Inc. | P1/2 | CCC · 48 |
| Carboplatin | Guangdong Provincial People's Hospital | P2 | CCC |
| Ceritinib | University of California, San Francisco | P2 | CCC |
| Regorafenib | University of California, San Francisco | P2 | CCC |
| Toripalimab | Guangdong Provincial People's Hospital | P2 | CCC |
| Entrectinib | University of California, San Francisco | P2 | CCC |
| Pralsetinib, Trans- | Fudan University | P1/2 | CCC |
| TAS0953 | Taiho Pharmaceutical Co., Ltd. | P1/2 | CCC |
| HM06 | Taiho Pharmaceutical Co., Ltd. | P1/2 | CCC |
+5 more in the RET Fusion Positive Cancer cohort
Other indications for Enbezotinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Medullary Thyroid Gland Carcinoma | — | P1/2 | CCC · 48 |
| Non-Small Cell Lung Carcinoma | — | P1/2 | CC · 41 |
| Cancer | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Enbezotinib in RET Fusion Positive Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/enbezotinib-ret-fusion-positive-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →